Patients
| Country | Value | Year |
|---|---|---|
| Lebanon | 500 | 2025 |
| Qatar | 200 | 2025 |
| Saudi Arabia | 1,300 | 2025 |
| Syria | 100 | 2025 |
| UAE | 200 | 2025 |
| Yemen | 1,200 | 2025 |
Updated
Reviewed by Vidhi Upadhyay
Middle East Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$499.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $88.7 Mn | — | — |
| 2025 (base) | $107.5 Mn | +$18.8 Mn | — |
| 2026 (forecast) | $130.3 Mn | +$22.8 Mn | +21.2% |
| 2027 (forecast) | $158.0 Mn | +$27.6 Mn | +46.9% |
| 2028 (forecast) | $191.4 Mn | +$33.5 Mn | +78% |
| 2029 (forecast) | $232.0 Mn | +$40.6 Mn | +115.8% |
| 2030 (forecast) | $281.2 Mn | +$49.2 Mn | +161.5% |
| 2031 (forecast) | $340.8 Mn | +$59.6 Mn | +217% |
| 2032 (forecast) | $413.1 Mn | +$72.3 Mn | +284.2% |
| 2033 (forecast) | $500.7 Mn | +$87.6 Mn | +365.6% |
| 2034 (forecast) | $606.8 Mn | +$106.1 Mn | +464.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $107.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $606.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 21.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Use, drug and end user (see all) |
| Key players | ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.
Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.
The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Lebanon | 500 | 2025 |
| Qatar | 200 | 2025 |
| Saudi Arabia | 1,300 | 2025 |
| Syria | 100 | 2025 |
| UAE | 200 | 2025 |
| Yemen | 1,200 | 2025 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East
Middle East
Middle East
Middle East
Middle East
Middle East
Medical Devices · Middle East
Medical Devices · Middle East
OTC & Nutraceuticals · Middle East
Medical Devices · Middle East
Healthcare Services · Middle East
Public Health · Middle East